Aug: Reported initial safety results from first Phase I/II trial - no significant adverse events found
June: Initiated Phase I/II trial in 63 healthy adult volunteers
Feb: Concluded GLP toxicology study
2008
November: Commenced a repeated (3 dose) GLP toxicology study using the maximal human dose
July: Pre-IND Meeting. BiondVax presented its pre- and clinical plans for the Multimeric-001 universal flu vaccine to the FDA in a Pre-IND meeting
2007
Nov: Voluntarily terminated first Phase I trial
Oct: Avian flu study in collaboration with Israeli Veterianrian Institute
July: Commenced Phase I clinical trial of 1st Generation vaccine
June: IPO on the Tel Aviv Stock Exchange, raising about $3m
2006
Conducted pre-clinical and toxicology studies
Production of 1st Generation vaccine
2005
Company operations begin
Initial fundraising round completed
2004
Initial fundraising round commenced
2003
Signed a license agreement with the Weizmann Institute for the in-licensing to BiondVax of the patent relating to the Peptide-based Vaccine for Influenza
BiondVax Pharmaceuticals Ltd. established as an Israeli company
1988 - 2002
15 years of R&D led by Prof. Ruth Arnon and her team at the Weizmann Institute of Science
Established feasibility of Universal Peptide-based Influenza Vaccine in animals
